Publication Date
10-1-2023
Journal
Nature Metabolism
DOI
10.1038/s42255-023-00889-6
PMID
37709961
PMCID
PMC11610247
PubMedCentral® Posted Date
12-2-2024
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Humans, Blood Glucose, Insulin, Diabetes Mellitus, Type 2, Adiposity, Obesity
Abstract
The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in patients with type 2 diabetes (T2D) and obesity 1, 2. The impact of genetic variability of GLP1R on receptor function and its association with metabolic traits are unclear with conflicting reports. Here, we performed a functional profiling of 60 GLP1R variants across four signaling pathways and revealed an unexpected diversity of phenotypes ranging from defective cell surface expression to complete or pathway-specific gain- (GoF) and loss-of-functions (LoF). The defective insulin secretion of GLP1R LoF variants was rescued by allosteric GLP1R ligands or high concentrations of exendin-4/semaglutide in INS-1 823/3 cells. Genetic association studies in 200K participants from the UK Biobank show that impaired GLP1R cell surface expression contributes to poor glucose control and increased adiposity with increased HbA1c, BMI and diastolic blood pressure. This study defines impaired GLP1R cell surface expression as a risk factor for T2D- and obesity-associated traits and provides potential treatment options for GLP1R LoF variant carriers.
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Genetics and Genomics Commons, Medical Genetics Commons, Medical Molecular Biology Commons, Medical Specialties Commons
Comments
Associated Data